Who
Elaine D. Sun
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals; Director, Dynavax Technologies; SVP, Chief Financial Officer, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 2 Mar 2020
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax TechnologiesBiotechnology | SEC FORM 4 Code D | —29,865 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,250 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —11,250 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —28,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologies | SEC FORM 4 Code D | —29,865 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,016 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —11,008 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologies | SEC FORM 4 Code A | —5,758 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,099 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —36,549 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.